Staar Surgical Stock (STAA) Soars on $1.5B Alcon Deal
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Stephen Farrell, CEO of Staar Surgical, said, 'As a significantly larger company, Alcon has the capabilities and scale to accelerate EVO ICL adoption and bring our innovative technology to more surgeons and patients worldwide.'
Staar Surgical and Alcon expect the deal to close within six to 12 months. It already has the support of both companies' boards of directors. Alcon also expects the deal to be accretive to its earnings in the second year after the deal is complete.
Staar Surgical Stock Movement Today
Staar Surgical stock was up 44.73% in pre-market trading on Tuesday, following a 4.11% rally yesterday. However, the shares have fallen 23.88% year-to-date and 51.2% over the past 12 months. Today's news came with heavy trading, as some 8 million shares changed hands, compared to a three-month daily average of about 678,000 units.
Is Staar Surgical Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts' consensus rating for Staar Surgical is Hold, based on two Buy, two Hold, and a single Sell rating over the past three months. With that comes an average STAA price target of $19.29, representing a potential 4.33% upside for the shares.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 days ago
- Yahoo
UBS: Time to cut back on cyclicals, favor select defensives
-- UBS said in a note Friday that investors should scale back exposure to most cyclical stocks outside of a few favored areas, citing weakening macro trends, stretched valuations, and seasonal underperformance risks. 'We are overweight financials and tech, electrification and domestic European consumer,' UBS strategists wrote, but stressed it is 'appropriate to lighten up on cyclicals outside of these areas in general.' The firm expects U.S. domestic demand to slow sharply, from 2.3% year-over-year in Q2 to 0.5% in Q4, and forecasts the U.S. 10-year yield at 3.8% by year-end. Historically, cyclicals have underperformed 84% of the time when volatility rises, UBS noted. Valuations are seen as another concern. The price-to-earnings ratio of cyclicals (excluding tech and financials) is '1.8 standard deviations above its norm in Europe and 1.4 standard deviations above in the U.S.' Meanwhile, the bank said most cyclical segments are crowded, with only paper and transport screens notably cheap. UBS recommends increasing exposure to defensive sectors with 'high profitability but low volatility of CFROI,' highlighting beverages, healthcare equipment, household products, select utilities, software, and non-U.S. defense. "Defensive sectors that score well on our screens are: beverages (we are benchmark), healthcare equipment (overweight) and household products (move to overweight)," the bank wrote. "Our preferred defensive sectors remain: parts of utilities, healthcare equipment, software and flavouring companies, non-US defence (India, Japan), European telecoms and UK food retailing." They highlighted names such as Alcon (NYSE:ALC), Abbot, DSM, Boston Scientific (NYSE:BSX), Orange, DT, BAE Systems (LON:BAES), Tesco (OTC:TSCDY), MSFT, SAP, Air Liquide (OTC:AIQUY), ENEL, ELIA, RWE (LON:0HA0), Entergy (NYSE:ETR), NiSource (NYSE:NI) and ConvaTec. The firm has raised household products to overweight, calling the European sector 'abnormally cheap against food' and noting its resilience and emerging market revenue exposure. Healthcare equipment is also a top pick. 'Price momentum is now 15% below its 6-month moving average… more than at any point in the past decade,' UBS said, adding that valuations are at a rare discount and earnings revisions are strong. Conversely, UBS advises trimming capital goods in the near term, warning they are 'very overbought' with a sharp disconnect between performance and earnings trends. Related articles UBS: Time to cut back on cyclicals, favor select defensives Victoria's Secret Exposed: The Warning Sign Behind the Stock's 52% Collapse Apollo economist warns: AI bubble now bigger than 1990s tech mania Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Associated Press
5 days ago
- Associated Press
STAAR SURGICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of STAAR Surgical Company
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Aug 7, 2025-- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of STAAR Surgical Company (NasdaqGM: STAA) to Alcon Inc. (NYSE: ALC). Under the terms of the proposed transaction, shareholders of STAAR will receive $28.00 in cash for each share of STAAR that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( [email protected] ) toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn View source version on CONTACT: Lewis S. Kahn, 855-768-1857 KSF Managing Partner [email protected] Swick & Foti, LLC 1100 Poydras St., Suite 960 New Orleans, LA 70163 KEYWORD: UNITED STATES NORTH AMERICA LOUISIANA NEW YORK INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL SOURCE: Kahn Swick & Foti, LLC Copyright Business Wire 2025. PUB: 08/07/2025 11:39 AM/DISC: 08/07/2025 11:38 AM
Yahoo
5 days ago
- Yahoo
Saudi Arabia OTC Artificial Tears Market Forecast and Company Analysis Report 2025-2033 Featuring AbbVie, Akorn, Alcon, Bausch Health, J&J, Nicox, Novartis, Santen Pharmaceutical, Sun Pharmaceutical
The Saudi Arabia OTC Artificial Tears Market is projected to reach USD 79.09 million by 2033, growing at a CAGR of 4.22% from 2025. Contributing factors include a rising elderly population, increased incidence of dry eye syndrome, and greater use of digital screens. Enhanced awareness of eye health, expanding retail and online pharmacies, and favorable healthcare policies are also promoting market growth. Non-prescription artificial tears offer convenient solutions for mild to moderate conditions. Despite regulatory hurdles and high competition, companies like AbbVie, Alcon, and Johnson & Johnson are key players in this growing market. Saudi Arabian OTC Artificial Tears Market Dublin, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia OTC Artificial Tears Market - Demand & Forecast 2025-2033" report has been added to Arabia OTC Artificial Tears Market is expected to reach US$ 79.09 million by 2033 from US$ 54.52 million in 2024, with a CAGR of 4.22% from 2025 to 2033. The growing elderly population, rising incidence of dry eye syndrome, increased usage of screens, improving awareness of eye health, increasing number of retail pharmacies, favorable healthcare policies, and the improving demand for convenient, non-prescription eye drops are all contributing factors to the growth of the OTC artificial tears market in Saudi Arabia. Over-the-counter (OTC) artificial tears in the form of non-prescription eye drops treat dryness and irritation caused by the insufficient production of tears. They moisten and lubricate the eye surface by mimicking natural tears. Artificial tears, which are commonly employed for burning, itching, and grittiness in the eyes, are employed for the treatment of dry eye syndrome, computer vision syndrome, environmental irritation, and contact lens irritation. They come in a range of formulations, such as preservative-free versions for sensitive eyes. Over-the-counter (OTC) artificial tears without a prescription are an easy first-line treatment option for mild, moderate, and even more severe dry eye symptoms and can be easily accessed in pharmacies and retail market for over-the-counter artificial tears is increasingly expanding due to various significant causes. The increasing prevalence of dry eye syndrome, spurred on by aging populations, greater use of screens, and environmental conditions such as dry climate and pollution of the air, is a strong contributory factor. There are more people using over-the-counter solutions for simple, self-administered treatment now that awareness of eye health is greater. Formulations are becoming safer and more appealing through innovation, such as preservative-free and biocompatible options, particularly for sensitive individuals. OTC artificial tears are also gaining popularity and ease of use with improved packaging and delivery systems and greater availability through retail and online Drivers for the Saudi Arabia OTC Artificial Tears Market Rising Prevalence of Dry Eye ConditionsIncreased incidence of dry eye disorders is one of the key drivers fueling the Saudi Arabian market for over-the-counter artificial tears. Based on a 2022 survey known as the Twaiq Mountain Eye Study, 16.4% of Saudi individuals with DED have severe symptoms, and 49.5% of them had the disease in general. Dryness of the ocular surface is exacerbated by the country's dry climate, excessive air pollution, and widespread air conditioning use, among other contributing factors. Additionally, 39.76% of Saudi Arabian students of health sciences who were involved in a PubMed study indicated symptoms such as dry eyes caused by digital eye strain. These findings validate the increasing reliance of consumers on non-prescription eye care products like artificial Preference for Non-Prescription SolutionsThe Saudi Arabian market for non-prescription artificial tears is expanding primarily because of consumer preference for non-prescription remedies. To relieve mild to moderate eye irritation, an increasing number of individuals are reaching for over-the-counter remedies due to growing self-care information and awareness of the eye. OTC artificial tears, which dispense with the need for prescription medication and visits to clinics, are easy and affordable, which makes them a contributing factor. Moreover, customers are looking for quick, convenient solutions because of the embarrassment surrounding repeated doctor visits for minor illnesses. E-commerce stores and retail drugstores enable this trend by providing a wide array of artificial tears products conveniently accessible. This shift is in line with wider trends in consumer health emphasizing proactive wellness management and of Retail and Online Distribution ChannelsThe Saudi Arabian market for non-prescription artificial tears is expanding rapidly due to the expansion of retail and online channels for distribution. The number and range of pharmacies and optical stores distributing eye care products have increased tremendously due to the country's Vision 2030 initiative, which has led to huge investments in the retail sector. For both urban and rural areas, the expansion enhances consumer convenience to eye care items, including artificial tears. Secondly, the rise of e-commerce sites has transformed the retail market by allowing customers to easily purchase eye care products from home. The sector is expanding due to the fact that online pharmacies often offer a broader product array, competitive prices, and detailed product in the Saudi Arabia OTC Artificial Tears Market Regulatory HurdlesOne major obstacle in the Saudi Arabian market for over-the-counter artificial tears is regulatory barriers. The distribution and certification of eye care goods, including artificial tears, are subject to stringent rules. Local health regulations must be followed by manufacturers, which can be expensive and time-consuming. Furthermore, delays in product releases or modifications to packaging and labeling may result from periodic changes in regulatory requirements. Both domestic and foreign firms wishing to enter the market may encounter obstacles due to these regulatory complications, which could limit product variety and raise consumer costs. In the long run, these difficulties can impede innovation and market CompetitionIn the Saudi Arabian market for over-the-counter artificial tears, fierce competition is a major obstacle. Due to the abundance of local and foreign brands on the market, there is fierce competition for consumers' attention. To stand out, businesses must make significant investments in price, product uniqueness, and marketing as a result of this saturation. Additionally, it may be challenging for new or smaller businesses to acquire momentum when there are well-known, worldwide brands present. Competition is heightened by consumers' price sensitivity, as companies compete to provide the best value without sacrificing product quality. This pressure from competitors may reduce profit margins and impede market expansion. Key Players Analysis: Company Overview, Key Persons, Recent Development & Strategies, Sales Analysis AbbVie Inc. Akorn Inc. Alcon Bausch Health Companies Inc. Johnson & Johnson Nicox S.A. Novartis AG Santen Pharmaceutical Co. Ltd. Sun Pharmaceutical Industries Ltd. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $54.52 Million Forecasted Market Value (USD) by 2033 $79.09 Million Compound Annual Growth Rate 4.2% Regions Covered Saudi Arabia Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Saudi Arabia OTC Artificial Tears Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Product Type6.2 By Application6.3 By Distribution Channel7. Product Type7.1 Solution7.2 Ointment7.3 Emulsion7.4 Gel7.5 Spray Solution7.6 Suspensions8. Application8.1 Dry Eye Syndrome8.2 Allergies8.3 Infections8.4 UV and Blue Light Protection8.5 Contact Lens Moisture Retention8.6 Others9. Distribution Channel9.1 Drugstores & Supermarkets9.2 Online Pharmacies9.3 Retail Pharmacies9.4 Others10. Porter's Five Forces Analysis10.1 Bargaining Power of Buyers10.2 Bargaining Power of Suppliers10.3 Degree of Competition10.4 Threat of New Entrants10.5 Threat of Substitutes11. SWOT Analysis11.1 Strength11.2 Weakness11.3 Opportunity11.4 Threats12. Key Players Analysis12.1 AbbVie Inc.12.1.1 Overviews12.1.2 Key Person12.1.3 Recent Developments12.1.4 Revenue12.2 Akorn Inc.12.2.1 Overviews12.2.2 Key Person12.2.3 Recent Developments12.2.4 Revenue12.3 Alcon12.3.1 Overviews12.3.2 Key Person12.3.3 Recent Developments12.3.4 Revenue12.4 Bausch Health Companies Inc.12.4.1 Overviews12.4.2 Key Person12.4.3 Recent Developments12.4.4 Revenue12.5 Johnson & Johnson12.5.1 Overviews12.5.2 Key Person12.5.3 Recent Developments12.5.4 Revenue12.6 Nicox S.A.12.6.1 Overviews12.6.2 Key Person12.6.3 Recent Developments12.6.4 Revenue12.7 Novartis AG12.7.1 Overviews12.7.2 Key Person12.7.3 Recent Developments12.7.4 Revenue12.8 Santen Pharmaceutical Co. Ltd.12.8.1 Overviews12.8.2 Key Person12.8.3 Recent Developments12.8.4 Revenue12.9 Sun Pharmaceutical Industries Ltd.12.9.1 Overviews12.9.2 Key Person12.9.3 Recent Developments12.9.4 RevenueCompanies Featured AbbVie Inc. Akorn Inc. Alcon Bausch Health Companies Inc. Johnson & Johnson Nicox S.A. Novartis AG Santen Pharmaceutical Co. Ltd. Sun Pharmaceutical Industries Ltd. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Saudi Arabian OTC Artificial Tears Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
